177 related articles for article (PubMed ID: 29160911)
1. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin Intensifies the Proapoptotic Activity of LFM-A13 in Cells and in a Mouse Model of Colorectal Cancer.
Tankiewicz-Kwedlo A; Hermanowicz JM; Pawlak K; Czarnomysy R; Bielawski K; Prokop I; Pawlak D
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690619
[TBL] [Abstract][Full Text] [Related]
3. The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.
Rozkiewicz D; Hermanowicz JM; Tankiewicz-Kwedlo A; Sieklucka B; Pawlak K; Czarnomysy R; Bielawski K; Surazynski A; Kalafut J; Przybyszewska A; Koda M; Jakubowska K; Rivero-Muller A; Pawlak D
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1697-1711. PubMed ID: 32912025
[TBL] [Abstract][Full Text] [Related]
4. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
[TBL] [Abstract][Full Text] [Related]
5. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton's tyrosine kinase and polo-like kinases, against human leukemic B-cell precursors.
Uckun F; Dibirdik I; Sarkissian A; Qazi S
Arzneimittelforschung; 2011; 61(4):252-9. PubMed ID: 21650085
[TBL] [Abstract][Full Text] [Related]
7. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).
Uckun FM; Dibirdik I; Qazi S; Vassilev A; Ma H; Mao C; Benyumov A; Emami KH
Bioorg Med Chem; 2007 Jan; 15(2):800-14. PubMed ID: 17098432
[TBL] [Abstract][Full Text] [Related]
8. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
[TBL] [Abstract][Full Text] [Related]
9. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice.
Sahin K; Tuzcu M; Yabas M; Orhan C; Sahin N; Ozercan IH
Invest New Drugs; 2018 Jun; 36(3):388-395. PubMed ID: 29139009
[TBL] [Abstract][Full Text] [Related]
10. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
[TBL] [Abstract][Full Text] [Related]
11. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Cetkovic-Cvrlje M; Uckun FM
Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinases.
Uckun FM
Cell Cycle; 2007 Dec; 6(24):3021-6. PubMed ID: 18073537
[TBL] [Abstract][Full Text] [Related]
13. In vivo toxicity and antithrombotic profile of the oral formulation of the antileukemic agent, LFM-A13-F.
Tibbles HE; Samuel P; Erbeck D; Mahajan S; Uckun FM
Arzneimittelforschung; 2004; 54(6):330-9. PubMed ID: 15281619
[TBL] [Abstract][Full Text] [Related]
14. Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. II. Effects of LFM-A13, a specific Btk inhibitor.
Gilbert C; Levasseur S; Desaulniers P; Dusseault AA; Thibault N; Bourgoin SG; Naccache PH
J Immunol; 2003 May; 170(10):5235-43. PubMed ID: 12734372
[TBL] [Abstract][Full Text] [Related]
15. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
[TBL] [Abstract][Full Text] [Related]
16. [Role of Bruton's tyrosine kinase in endotoxin/lipopolysaccharide-induced pyroptosis of intestinal cells in scalded mice].
Jin X; Wan J; Duan SF; Gong YZ; Wang F; Chen XL
Zhonghua Shao Shang Za Zhi; 2021 Jun; 37(6):546-554. PubMed ID: 34139835
[No Abstract] [Full Text] [Related]
17. Preclinical toxicity and pharmacokinetics of the Bruton's tyrosine kinase-targeting anti-leukemic drug candidate, alpha-cyano-beta-hydroxy-beta-methyl-N- (2,5-dibromophenyl) propenamide (LFM-A13).
Uckun FM; Tibbles H; Venkatachalam T; DuMez D; Erbeck D
Arzneimittelforschung; 2007; 57(1):31-46. PubMed ID: 17341007
[TBL] [Abstract][Full Text] [Related]
18. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
Ghosh S; Mohammed Z; Singh I
J Neuroinflammation; 2021 Dec; 18(1):289. PubMed ID: 34895246
[TBL] [Abstract][Full Text] [Related]
19. Bruton's tyrosine kinase as a new therapeutic target.
Uckun FM; Tibbles HE; Vassilev AO
Anticancer Agents Med Chem; 2007 Nov; 7(6):624-32. PubMed ID: 18045057
[TBL] [Abstract][Full Text] [Related]
20. TLR7 (Toll-Like Receptor 7) Facilitates Heme Scavenging Through the BTK (Bruton Tyrosine Kinase)-CRT (Calreticulin)-LRP1 (Low-Density Lipoprotein Receptor-Related Protein-1)-Hx (Hemopexin) Pathway in Murine Intracerebral Hemorrhage.
Wang G; Guo Z; Tong L; Xue F; Krafft PR; Budbazar E; Zhang JH; Tang J
Stroke; 2018 Dec; 49(12):3020-3029. PubMed ID: 30571407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
